Financial Reports

Friday, August 29, 2014

Alchemia today announced its results for the financial year 2014 with new high-calibre appointments to the board and management, and substantial progress achieved across all its drug platforms during the year.

Thursday, February 20, 2014

Highlights from half-year results include total revenue of $5.0m for 6 months to 31 December 2013 including $4.7m in fondaparinux profit share payments, and a cash balance of $16.4m as at 31 December 2013 inclusive of $8.8m in R&D tax incentives.

Monday, February 17, 2014

The company, today reports profit share of A$2.8 million (US$2.5 million) for the quarter ended 31 December 2013, on sales of its generic anti-coagulant drug fondaparinux.

Friday, August 30, 2013
Thursday, August 22, 2013
Tuesday, September 4, 2012
Wednesday, August 22, 2012

Pages